137 related articles for article (PubMed ID: 23867391)
1. Downregulation of EIF4A2 in non-small-cell lung cancer associates with poor prognosis.
Shaoyan X; Juanjuan Y; Yalan T; Ping H; Jianzhong L; Qinian W
Clin Lung Cancer; 2013 Nov; 14(6):658-65. PubMed ID: 23867391
[TBL] [Abstract][Full Text] [Related]
2. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer.
Yang J; Liu H; Wang H; Sun Y
Pathol Res Pract; 2013 Aug; 209(8):490-4. PubMed ID: 23827213
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients.
Kato T; Daigo Y; Aragaki M; Ishikawa K; Sato M; Kondo S; Kaji M
Lung Cancer; 2011 Oct; 74(1):124-31. PubMed ID: 21376419
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer.
Yip PY; Cooper WA; Kohonen-Corish MR; Lin BP; McCaughan BC; Boyer MJ; Kench JG; Horvath LG
J Clin Pathol; 2014 Apr; 67(4):333-40. PubMed ID: 24265323
[TBL] [Abstract][Full Text] [Related]
6. Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer.
Hansen LV; Skov BG; Ploug M; Pappot H
Lung Cancer; 2007 Nov; 58(2):260-6. PubMed ID: 17706320
[TBL] [Abstract][Full Text] [Related]
7. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
8. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer.
Gu J; Ding JY; Lu CL; Lin ZW; Chu YW; Zhao GY; Guo J; Ge D
Lung Cancer; 2013 Aug; 81(2):259-65. PubMed ID: 23706417
[TBL] [Abstract][Full Text] [Related]
11. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
12. [Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].
Li Y; Sun BS; Zhang ZF; Zhang LM; Wang CL
Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(24):1682-6. PubMed ID: 21914316
[TBL] [Abstract][Full Text] [Related]
13. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer.
Wang L; Soria JC; Kemp BL; Liu DD; Mao L; Khuri FR
Clin Cancer Res; 2002 Sep; 8(9):2883-9. PubMed ID: 12231532
[TBL] [Abstract][Full Text] [Related]
14. Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer.
Võsa U; Vooder T; Kolde R; Fischer K; Välk K; Tõnisson N; Roosipuu R; Vilo J; Metspalu A; Annilo T
Genes Chromosomes Cancer; 2011 Oct; 50(10):812-22. PubMed ID: 21748820
[TBL] [Abstract][Full Text] [Related]
15. Low expression of olfactomedin 4 correlates with poor prognosis in smoking patients with non-small cell lung cancer.
Su W; Luo L; Wu F; Lai Z; Li X; Xie Z; Tang Z; Yang Z; Liang R
Hum Pathol; 2015 May; 46(5):732-8. PubMed ID: 25771901
[TBL] [Abstract][Full Text] [Related]
16. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis.
Pelletier MP; Edwardes MD; Michel RP; Halwani F; Morin JE
Can J Surg; 2001 Jun; 44(3):180-8. PubMed ID: 11407827
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.
Han CH; Cho JY; Moon JT; Kim HJ; Kim SK; Shin DH; Chang J; Ahn CM; Kim SK; Chang YS
Oncol Rep; 2006 Dec; 16(6):1205-10. PubMed ID: 17089038
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
[TBL] [Abstract][Full Text] [Related]
19. Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer.
Hsu NY; Wu JY; Liu X; Yen Y; Chen CY; Chou MC; Lin CH; Lee H; Cheng YW
Anticancer Res; 2011 Oct; 31(10):3475-81. PubMed ID: 21965764
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer.
Xu YH; Lu S
Eur J Surg Oncol; 2014 Mar; 40(3):311-7. PubMed ID: 24332948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
